GOG 0186K: A Randomized Phase II Study of Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in The Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Female Reproductive Cancer
This is a clinical trial of Cabozantinib that will be administered by mouth, which is investigational and Paclitaxel that will be administered by IV and is standard of care.
IRB Protocol #
REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period(s) that can last up to 5 years. A follow up period will consist of clinic visit. // Eligibility criteria include but are not limited to 18 years or older with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Eligibility criteria include but are not limited to 18 years or older with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.